Current report No. 26/2022 – Conclusion of the agreement on joint development and commercialization of an inhalation drug containing fluticasone and salmeterol in the US

Current report No. 26/2022 Date prepared: 29/11/2022 Abbreviated name of the issuer: CELON PHARMA S.A. Topic     Conclusion of the agreement on joint development and commercialization of an inhalation drug containing fluticasone and salmeterol in the US Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Content of the report:Read more »

Current report No. 25/2022 – Celon Pharma S.A.’s project on a new therapeutic objective for the FGF1 protein analogue will receive co-funding

Current report No. 25/2022 Date prepared: November 21, 2022, time: 03:54 PM Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Celon Pharma S.A.’s project on a new therapeutic objective for the FGF1 protein analogue will receive co-funding Legal basis: Article 17 (1) of the Market Abuse Regulation (MAR) – inside information. Content of theRead more »

Current report No. 24/2022 – Celon Pharma S.A.’s project on improving drug safety by implementing innovative forms of orally administered medicinal products to the Company’s in-house production will receive co-funding

Date prepared: 11/08/2022Legal basis: Article 17 (1) of the Market Abuse Regulation (MAR) – inside information, time: 07:45 PM Content of the report: The Management Board of Celon Pharma S.A. (“Company”) wishes to announce that on November 8, 2022 it received information that the Company’s application for co-funding of a project entitled “CardioCAPS – ImprovingRead more »

Current report No. 22/2022 – Decision of the Central Securities Depository of Poland (KDPW) on assimilation of 5,000 C share actions with the Company’s share in the stock exchange trading

Current report No. 22/2022Date prepared: 18/07/2022Abbreviated name of the issuer: CELON PHARMA S.A.Subject: Decision of the Central Securities Depository of Poland (KDPW) on assimilation of 5,000 C share actions with the Company’s share in the stock exchange tradingLegal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodicalRead more »

Current report 21/2022 – Admission and introduction of 5,000 ordinary C-series bearer shares of the Company to stock exchange trading

Current report No. 21/2022 Date prepared: 15/07/2022 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Admission and introduction of 5,000 ordinary C-series bearer shares of the Company to stock exchange trading Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report:Read more »

Current report No. 20/2022 – Summary of subscription of ordinary C-series bearer shares in Celon Pharma S.A. Performed under the 2021 Incentive Program

Current report No. 20/2022 Date prepared: 08/07/2022 Abbreviated name of the issuer: Celon Pharma S.A. Subject: Summary of subscription of ordinary C-series bearer shares in Celon Pharma S.A. performed under the Incentive Program for 2021 Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information ContentRead more »

Current report No. 18/2022 – List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company held on June 22, 2022

Current report No. 18/2022 Date prepared: June 23, 2022 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company held on June 22, 2022 Legal basis subs. 70 point 3 of the Act on Public Offering – GeneralRead more »